Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 1/20 | 0.40 |
| ▸ | CHKA | P35790 | 1/20 | 0.40 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17103466 | 0.82 | — | — | |
| SCHEMBL17103290 | 0.82 | — | — | |
| SCHEMBL7962887 | 0.69 | L3MBTL1 (0.37) | — | |
| SCHEMBL446894 | 0.67 | — | — | |
| SCHEMBL13721022 | 0.67 | — | — | |
| SCHEMBL16538344 | 0.66 | KIF11 (0.42) | — | |
| SCHEMBL792392 | 0.62 | TRPV4 (0.37) | CA2CHKATRPV4 | |
| SCHEMBL17103362 | 0.62 | — | — | |
| SCHEMBL73269 | 0.62 | LOXL2 (0.35) | CA2CHKATRPV4 | |
| SCHEMBL789989 | 0.60 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 259 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | BREYE THERAPEUTICS APS (DK) | 2024-02-01 | — | — | US | claimed |
| EP-4262975-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | Breye Therapeutics ApS (DK) | 2023-10-25 | — | — | EP | claimed |
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | MOLECURE S.A. (PL) | 2023-09-07 | — | — | US | claimed |
| WO-2022129365-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | AXXAM S.P.A. (IT) | 2022-06-23 | — | — | WO | claimed |
| EP-4015039-A1 | HETEROCYCLIC DERIVATIVES AS P2X7 RECEPTOR ANTAGONISTS | AXXAM S.p.A. (IT) | 2022-06-22 | — | — | EP | claimed |
| EP-3019480-B1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | AGIOS PHARMACEUTICALS INC (US) | 2020-05-06 | — | — | EP | claimed |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | AGIOS PHARMACEUTICALS, INC. (US) | 2019-08-13 | — | — | US | claimed |
| CN-103596937-B | Substituted benzamide derivatives | 霍夫曼-拉罗奇有限公司 | 2016-06-29 | — | — | CN | claimed |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | SERVIER PHARMACEUTICALS LLC | 2016-06-09 | — | — | US | claimed |
| EP-3019480-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | claimed |
| WO-2012168265-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | F. HOFFMANN-LA ROCHE AG (CH) | 2012-12-13 | — | — | WO | claimed |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | HOFFMANN-LA ROCHE INC. | 2012-12-13 | — | — | US | claimed |
| WO-2012129338-A1 | AZOLE COMPOUNDS AS PIM INHIBITORS | AMGEN INC. (US) | 2012-09-27 | — | — | WO | claimed |
| EP-2491031-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | Janssen Pharmaceutica N.V. (BE) | 2012-08-29 | — | — | EP | claimed |
| WO-2011050202-A1 | FUSED HETEROCYCLIC COMPOUNDS AS OREXIN RECEPTOR MODULATORS | JANSSEN PHARMACEUTICA NV (BE) | 2011-04-28 | — | — | WO | claimed |
| US-20100227844-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK SHARP & DOHME CORP. | 2010-09-09 | — | — | US | claimed |
| WO-2009054929-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | MERCK & CO., INC. (US) | 2009-04-30 | — | — | WO | claimed |
| CN-1639112-A | Substituted amides having cannabinoid-1 receptor activity | MERCK & CO INC (US) | 2005-07-13 | — | — | CN | claimed |
| WO-2004048317-A1 | SUBSTITUTED AMIDES ACTIVE AT THE CANNABINOID-1 RECEPTOR | MERCK & CO., INC. (US) | 2004-06-10 | — | — | WO | claimed |
| US-6124294-A | COMPOUNDS HAVING HIGH AFFINITY FOR DOPAMINE D3 RECEPTOR; USED TO TREAT DISORDERS WHICH RESPOND TO DOPAMINE D3 LIGANDS | BASF AKTIENGESELLSCHAFT (DE) | 2000-09-26 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230278996-A1 | YKL-40 INHIBITORS AND THEIR THERAPEUTIC APPLICATIONS | CHI3L1, CHI3L2, CHIA | CA2 2790/4885CHKA 1567/4885TRPV4 2812/4885 |
| US-20100227844-A1 | CANNABINOID-1 RECEPTOR MODULATORS USEFUL FOR THE TREATMENT OF ALZHEIMER'S DISEASE | CNR1, CNR2, GPR18 | CA2 716/4885CHKA 320/4885TRPV4 615/4885 |
| US-20120316165-A1 | SUBSTITUTED BENZAMIDE DERIVATIVES | NPY4R, PER2, NPY1R | CA2 2365/4885CHKA 2083/4885TRPV4 463/4885 |
| US-20240034737-A1 | Heterocyclic Derivatives as P2X7 Receptor Antagonists | P2RX7, P2RX3, P2RX1 | CA2 1786/4885CHKA 2370/4885TRPV4 44/4885 |
| US-20160158230-A1 | 2,4- OR 4,6-DIAMINOPYRIMIDINE COMPOUNDS AS IDH2 MUTANTS INHIBITORS FOR THE TREATMENT OF CANCER | IDH2, IDH3B, IDH3A | CA2 1806/4885CHKA 2343/4885TRPV4 4869/4885 |
| US-10376510-B2 | 2,4- or 4,6-diaminopyrimidine compounds as IDH2 mutants inhibitors for the treatment of cancer | IDH2, IDH3B, IDH3A | CA2 1806/4885CHKA 2343/4885TRPV4 4869/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.